Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Pathogens and Immunity · 2024
DOI: 10.20411/pai.v10i1.752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens and Immunity, 2024. Verfasst von Delphine Planas und 13 weiteren Autor:innen. Beteiligte Einrichtung: Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Background
First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.
Methods
We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines.
Results
Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP.3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP.3.3.
Conclusions
Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
- Vaccine Research Institute, Créteil, France.
- Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
- National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.
- G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
- Bioinformatics and Biostatistics Hub, Paris, France.
Förderung
- NIAID NIH HHS
Zitieren
APA
Planas, D., Staropoli, I., Planchais, C., Yab, E., Jeyarajah, B., Rahou, Y., Prot, M., Guivel-Benhassine, F., Lemoine, F., Enouf, V., Simon-Loriere, E., Mouquet, H., Rameix-Welti, M. A., & Schwartz, O. (2024). Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies. Pathogens and Immunity. https://doi.org/10.20411/pai.v10i1.752
Vancouver
Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies. Pathogens and Immunity. 2024. doi:10.20411/pai.v10i1.752
BibTeX
@article{Planas2024,
author = {Planas, Delphine and Staropoli, Isabelle and Planchais, Cyril and Yab, Emilie and Jeyarajah, Banujaa and Rahou, Yannis and Prot, Matthieu and Guivel-Benhassine, Florence and Lemoine, Frederic and Enouf, Vincent and Simon-Loriere, Etienne and Mouquet, Hugo and Rameix-Welti, Marie-Anne and Schwartz, Olivier},
title = {Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies},
journal = {Pathogens and Immunity},
year = {2024},
doi = {10.20411/pai.v10i1.752}
}
EUVIMED